Fox Run Management L.L.C. Buys New Stake in AnaptysBio, Inc. $ANAB

Key Points

• Fox Run Management L.L.C. has acquired 27,796 shares of AnaptysBio, Inc. during the first quarter, amounting to approximately $517,000, giving it a 0.09% ownership in the company.
• Insider trading activity at AnaptysBio included Director Hollings Renton selling 20,925 shares, a significant 80.82% decrease in his position, valued at $493,202.25.
• Analysts have recently raised their price targets for AnaptysBio, with JPMorgan Chase increasing their estimate from $42.00 to $80.00, reflecting growing optimism about the company's performance.

Fox Run Management L.L.C. acquired a new position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 27,796 shares of the biotechnology company's stock, valued at approximately $517,000. Fox Run Management L.L.C. owned about 0.09% of AnaptysBio as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of ANAB. US Bancorp DE grew its position in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 979 shares during the last quarter. Farther Finance Advisors LLC grew its position in AnaptysBio by 9,778.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,858 shares during the last quarter. Tower Research Capital LLC TRC grew its position in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares during the last quarter. Virtus ETF Advisers LLC grew its position in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares during the last quarter.

AnaptysBio Trading Down 0.7%

NASDAQ ANAB traded down $0.14 on Friday, hitting $20.22. 257,922 shares of the company's stock traded hands, compared to its average volume of 483,118. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $40.70. The firm's 50-day moving average price is $23.64 and its two-hundred day moving average price is $20.69. The firm has a market capitalization of $566.16 million, a PE ratio of -4.51 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total value of $493,202.25. Following the completion of the transaction, the director directly owned 4,965 shares in the company, valued at $117,025.05. The trade was a 80.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 33.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ANAB shares. Wedbush boosted their target price on shares of AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Guggenheim reissued a "buy" rating and set a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. UBS Group reissued a "neutral" rating and set a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Finally, HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $46.13.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.